Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

Chinese mainland reports 5 locally transmitted COVID-19 cases, China's anti-COVID-19 drug enters late-stage human trial
Published on: 2021-11-23
Share to
User Rating: / 0
PoorBest 

The Chinese mainland on Monday reported five new locally transmitted COVID-19 cases, the National Health Commission said in its daily report on Tuesday.
 

Of the five local cases, four were reported in Liaoning and one in Yunnan, the commission said.
 

Monday also saw reports of 14 imported cases in six provincial-level regions, it said.
 

No new suspected cases or new deaths related to COVID-19 were reported on Monday, said the commission.
 

A Chinese antiviral medicine for COVID-19, called JS016, has commenced phase-3 clinical trials overseas, its developer said Monday.
 

The patented anti-COVID-19 drug candidate was jointly developed by the Institute of Microbiology under the Chinese Academy of Sciences and the Shanghai Junshi Biosciences Co Ltd.
 

According to the institute, JS016 has become the first COVID-19 monoclonal antibody in the world to carry out clinical trials in healthy people.
 

Researchers completed global multi-center phase-2 trials this month. The results of the early-stage trials support the safety and effectiveness of JS016, suggesting it can lower the viral titer in participants and reduce the risk of becoming a severe case.
 

一款具有我国自主知识产权的新冠肺炎治疗性抗体新药JS016正在积极推进Ⅲ期临床试验

JS016与另一中和抗体联合使用已获得全球15个国家紧急使用授权,安全性有效性获得世界性认可,为全球新冠肺炎疫情的防控提供了中国方案。
 

JS016是由中科院微生物所与上海君实生物联合开发的治疗性抗体新药,具有独特的靶向性,可针对新冠病毒精准进攻,能阻止病毒进入细胞,快速产生作用。
 

中国科学院微生物研究所研究员严景华:病毒要进入细胞的时候,它表面的蛋白要和人体细胞上的蛋白进行相互作用。抗体药物的机制就是阻断相互作用,相当于病毒要进一个门,它要一把钥匙开一把锁,现在把这个钥匙蒙住了,所以它就进不去了,通过这样一个机制阻断病毒的感染。
 

在科技部、中科院专项支持下,2020年6月5日JS016获得国内首个新冠单抗临床试验批件,也是国际上第一个在健康人体开展临床试验的新冠单抗。
 

本土新增5+2,两省32地降级,四川省全域为低风险!

国家卫健委23日通报,22日0时至24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增新冠肺炎本土确诊病例5例(辽宁4例,均在大连市;云南1例,在德宏傣族景颇族自治州)。新增本土无症状感染者2例(均在云南德宏傣族景颇族自治州)。
 

据四川省成都市成华区新型冠状病毒肺炎疫情防控指挥部消息,自2021年11月23日起,将成都市成华区理工东苑西区由高风险地区调整为低风险地区,兴元华盛二期由中风险地区调整为低风险地区,解除相关封控区、管控区圈层管理。截至目前,成都市中高风险地区全部清零,四川省全域为低风险地区。
 

大连市新冠肺炎疫情防控总指挥部发布,从2021年11月23日0时起,将大连市庄河市城关街道海洋村刘亮屯等30个中风险地区调整为低风险地区。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2021 BusinessTianjin.com. All rights reserved.